KYOWA-KIRIN
15.4.2024 15:16:28 CEST | Business Wire | Press release
On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subtypes of cutaneous T-cell lymphoma (CTCL).
CTCL is a rare form of non-Hodgkin lymphoma that most prominently affects the skin, presenting as patches, plaques, tumours, or reddening of the entire skin, and may be associated with severe itching. In a proportion of cases, the disease may spread to the lymph nodes, blood, and/or other organs.
In the current interim analysis, symptom scores (mean) were reported for 20 adult patients with relapsed or refractory disease (8 MF; 12 SS) over their first 16 weeks of mogamulizumab treatment. Prior to treatment initiation, patients reported their symptom burden using a 1 – 10 numeric scale. At baseline, skin itch scored highest (6.6) followed by skin redness (6.2), flaking skin (5.9) and skin pain (4.0). Additionally, over half of patients reported having sleep problems either “frequently” or “every night” while 47% reported difficulties regulating body temperature “frequently” or “always”.
Improvement in all symptoms was reported within 4 weeks of treatment initiation and by week 16, symptom severity had decreased considerably with the greatest improvement seen in skin redness (-2.9) closely followed by skin itch (-2.7), flaking skin (-2.5) and skin pain (-2.2). Of note, the proportion of patients reporting sleep problems or difficulties regulating body temperature either “frequently” or “always” decreased to less than 20%.
“We know that CTCL patients not only suffer from the stress of a cancer diagnosis, but that these stresses are compounded by painful, red, scaly, and itchy lesions, tumours, and varying levels of discomfort,” says study principal investigator, Prof. Julia Scarisbrick of the University of Birmingham. “The PROSPER study is helping us understand these burdens better and the impact mogamulizumab may have on patients’ symptoms and quality of life.”
To view the full press release, click here.
KKI/INT/MOG/1081
Date of Preparation: April 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415169712/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Abu Dhabi to Imola: A2RL Expands Internationally with Historic Autonomous Racing Debut at Iconic Italian Track29.6.2026 12:12:00 CEST | Press release
A2RL’s first international race marks a major step towards its ambition to become the world’s first international championship for fully autonomous racecarsUp to 5 teams including TUM, PoliMOVE, Unimore, Kinetiz and Constructorselected from the 2025 season will compete in the world’s first autonomous multi-car race in EuropeA2RL engaged Italy’s motorsport, engineering and student communities through Motor Valley Fest and a university roadshow ahead of the raceFollowing European debut at Imola, the 2026 season will conclude at Yas Marina Circuit in Abu Dhabi The Abu Dhabi Autonomous Racing League, A2RL, will make its international racing debut on 5 September 2026 in Imola, Italy, bringing up to 5 fully autonomous racecars based on the Dallara Super Formula SF23 to one of the world’s most iconic and demanding racing circuits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629726789/en/ From Abu Dhabi to Imola: A2RL Expands
Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”29.6.2026 12:00:00 CEST | Press release
A new platform for dialogue on progress, reflecting a mutual commitment to advancing positive change Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path. What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large. Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom